TLP
RIGL icon

Tri Locum Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Tri Locum Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,456
Closed -$51K – 70
2020
Q4 		$51K Buy
+1,456
New +$42.2K 0.02% 65

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tri Locum Partners's RIGL Position: Q1 2021 in Review

Tri Locum Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 1,456 shares — an estimated $51K sold.

Tri Locum Partners first reported a position in RIGL in Q4 2020 and held it in 1 quarter. The position peaked at $51K in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

  • Tri Locum Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 1,456 Rigel Pharmaceuticals shares in Q1 2021, an estimated $51K.
  • Tri Locum Partners first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's Rigel Pharmaceuticals position peaked at $51K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.